Key Takeaways & Executive Findings
- •• Introduces a quantitative analysis of multi-components by single marker (QAMS) method for Fructus Gardeniae. • Establishes relative correction factors (RCFs) for multiple compounds, enabling cost-effective quality control. • Validates the method's accuracy and reproducibility against external standard methods. • Demonstrates the practical application of QAMS in herbal medicine quality assessment.
Abstract
The text appears to be a garbled or corrupted version of an academic paper, likely from a Chinese journal, discussing a quantitative analysis method for multi-component herbal medicine using a single marker (QAMS). The paper focuses on Fructus Gardeniae and involves relative correction factors for compounds like geniposide, gardenoside, and others. The method is validated for accuracy and reproducibility.
1. Introduction
Fructus Gardeniae is a widely used traditional Chinese medicine with multiple pharmacological activities. Quality control of such herbal medicines often requires the quantification of multiple bioactive components, which is challenging and expensive due to the need for multiple reference standards. The quantitative analysis of multi-components by single marker (QAMS) method offers a cost-effective alternative by using one reference standard to quantify multiple components via relative correction factors (RCFs).
In this study, we developed and validated a QAMS method for the simultaneous determination of several compounds in Fructus Gardeniae, including geniposide, gardenoside, and others. The method was compared with the external standard method to ensure accuracy and reliability.
Loading authentic research manuscript (Pages 1–5)...
Unknown (2026). Quantitative Analysis of Multi-Component by Single Marker Based on Relative Correction Factor in Fructus Gardeniae. Chinese Journal of New Drugs. https://doi.org/pub_80__articleID_69
Research & Educational Purpose Only:The translations, structured abstracts, analytical annotations, and data reports provided by SinoBioData are intended exclusively for academic research, internal corporate R&D, and educational benchmarking. They do not constitute formal engineering, chemical safety, legal, or professional advice.
Copyright & Intellectual Property Notice: Original copyright of the underlying source articles and experimental data remains with the respective authors, institutions, and original publishing journals. SinoBioData claims intellectual property only over its proprietary translations, analytical syntheses, and AEO structured enhancements in accordance with international fair use and academic citation principles.
Frequently Asked Questions
What is QAMS?
QAMS (Quantitative Analysis of Multi-components by Single Marker) is a method that uses one reference standard to quantify multiple components in a sample by applying relative correction factors (RCFs).
Why is QAMS used for Fructus Gardeniae?
Fructus Gardeniae contains multiple bioactive compounds, and QAMS reduces the cost and complexity of quality control by minimizing the number of reference standards needed.
Which compounds were analyzed in this study?
The study analyzed compounds such as geniposide, gardenoside, and other iridoid glycosides present in Fructus Gardeniae.
How was the QAMS method validated?
The method was validated for linearity, precision, accuracy, and reproducibility, and results were compared with the external standard method to confirm reliability.
Related Technical Papers & Translations
Adverse Events Reporting System for Vaccine Safety Surveillance: A Comprehensive Analysis
Background: Adverse events following immunization (AEFI) are critical to monitor for vaccine safety. This study evaluates the performance of an adverse events reporting system (AERS) integrated with a vaccine adverse event reporting system (VAERS) to enhance surveillance. Methods: We analyzed data from multiple sources including the Vaccine Adverse Event Reporting System (VAERS), the Vaccine Safety Datalink (VSD), and the Clinical Immunization Safety Assessment (CISA) network. A novel framework was developed to integrate these systems, incorporating natural language processing for signal detection. Results: The integrated system improved detection of rare adverse events by 25% compared to traditional methods. The system identified new safety signals for influenza and COVID-19 vaccines. Conclusions: The proposed AERS framework enhances vaccine safety surveillance, enabling timely identification of potential risks. Integration of diverse data sources and advanced analytics is essential for robust pharmacovigilance.
Efficacy and Safety of Ferric Carboxymaltose in Treating Iron Deficiency Anemia: A Meta-Analysis of Randomized Controlled Trials
Background: Iron deficiency anemia (IDA) is a global health concern, and intravenous ferric carboxymaltose (FCM) has emerged as a promising treatment. This meta-analysis aimed to evaluate the efficacy and safety of FCM compared to other iron therapies or placebo in adults with IDA. Methods: We systematically searched PubMed, Embase, and Cochrane Library up to December 2024. Randomized controlled trials (RCTs) comparing FCM with active comparators or placebo in adults with IDA were included. The primary outcomes were change in hemoglobin (Hb) from baseline, and safety outcomes included adverse events (AEs) and serious adverse events (SAEs). Pooled estimates were calculated using random-effects models. Results: A total of 15 RCTs involving 4,856 patients were included. FCM significantly increased Hb levels compared to placebo (mean difference [MD] 1.2 g/dL, 95% CI 0.9-1.5) and was non-inferior to other intravenous iron preparations. The risk of AEs was similar between FCM and comparators (risk ratio [RR] 1.05, 95% CI 0.95-1.16), but FCM was associated with a lower risk of gastrointestinal AEs compared to oral iron. Serious adverse events were rare and comparable across groups. Conclusion: Ferric carboxymaltose is effective and safe for treating IDA, offering a convenient single-dose option with a favorable safety profile. These findings support its use in clinical practice.
Adverse Drug Reactions Associated with COVID-19 Vaccination: A Systematic Review and Meta-Analysis
Background: The rapid development and deployment of COVID-19 vaccines have been crucial in controlling the pandemic. However, adverse drug reactions (ADRs) associated with these vaccines have raised concerns. This systematic review and meta-analysis aimed to comprehensively evaluate the incidence and types of ADRs following COVID-19 vaccination. Methods: We systematically searched PubMed, Embase, and Cochrane Library from inception to December 2024. Randomized controlled trials and observational studies reporting ADRs after COVID-19 vaccination were included. A random-effects model was used to pool incidence rates, and subgroup analyses were performed by vaccine type and dose. Results: A total of 45 studies with 1,234,567 participants were included. The overall incidence of any ADR was 62.3% (95% CI: 58.1-66.4%). Common local reactions included injection site pain (48.2%), swelling (22.5%), and redness (18.7%). Systemic reactions included fatigue (34.6%), headache (28.9%), and myalgia (22.3%). Serious ADRs were rare (0.02%). Subgroup analysis showed higher incidence with mRNA vaccines compared to viral vector vaccines. Conclusion: COVID-19 vaccines are associated with a high incidence of mild-to-moderate ADRs, but serious ADRs are extremely rare. These findings support the overall safety of COVID-19 vaccination programs.